Industrial Transformation Training Centres - Grant ID: IC180100021
Funder
Australian Research Council
Funding Amount
$4,163,359.00
Summary
ARC Training Centre for the Development of Tools for Fragment Based Design. The ARC Training Centre for the Development of Tools for Fragment Based Design aims to inspire the next generation of drug discovery research leaders. It plans to provide direct experience with industry partners, training and master classes in early stage drug-discovery from industry experts. The Centre is expected to accelerate research translation and industry engagement by providing an efficient strategy for the scree ....ARC Training Centre for the Development of Tools for Fragment Based Design. The ARC Training Centre for the Development of Tools for Fragment Based Design aims to inspire the next generation of drug discovery research leaders. It plans to provide direct experience with industry partners, training and master classes in early stage drug-discovery from industry experts. The Centre is expected to accelerate research translation and industry engagement by providing an efficient strategy for the screening of a biological target and early medicinal chemistry for optimisation. The expected outcome of the Centre is to equip the trainees with the skills to make key contributions to the sustainability and growth of the sector and to provide significant capacity to address global challenges for 21st century pharmaceutical innovation.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
Understanding production and application of alpha emitting radionuclides. This project aims to develop new materials to improve the efficiency of production of radionuclides, as well as tools to improve our understanding of isotope decay products to to improve efficiency of delivery. High performance polymers will be evaluated to establish optimal design properties for enhanced radionuclide collection from novel generators of isotopic lead (Pb-212), and new methods will be developed to improve u ....Understanding production and application of alpha emitting radionuclides. This project aims to develop new materials to improve the efficiency of production of radionuclides, as well as tools to improve our understanding of isotope decay products to to improve efficiency of delivery. High performance polymers will be evaluated to establish optimal design properties for enhanced radionuclide collection from novel generators of isotopic lead (Pb-212), and new methods will be developed to improve understanding of isotope product stability. Anticipated outcomes will provide greater production and utility of radioisotopes in radiopharmaceuticals, while building strong ties with partner AdvanCell Isotopes. This could improve manufacture of radionuclides, expanding capability and applications in radiopharmaceuticals.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH190100021
Funder
Australian Research Council
Funding Amount
$4,999,540.00
Summary
ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A ....ARC Research Hub to Combat Antimicrobial Resistance. The ARC ITRP Research Hub to Combat Antimicrobial Resistance takes on the global challenge of antimicrobial resistance (AMR) for Australia through a world-first partnership between industry, researchers, and end users. The AMR Hub fosters a pre-commercialisation environment to address both social and laboratory-based preclinical challenges to provide a highly integrated diagnostic, pharmaceutical and end user solution to the problem of AMR. A goal of the Hub is to support the development of new molecular diagnostic technology, improve the processes for identifying potential antibiotic compounds and assess and advise on antimicrobial stewardship with a vision to transform social and health outcomes globally.Read moreRead less
Pharmacology Of Potential Anti-Tumour Agents: Iron Chelators Of The BpT Class
Funder
National Health and Medical Research Council
Funding Amount
$585,455.00
Summary
Pharmacology of Potential Anti-Tumour Agents: Iron Chelators of the BpT Class Cancer cells have a high iron requirement for DNA synthesis and many clinical trials showed Fe chelators are effective anti-cancer drugs. Their potential to act as anti-tumour agents has been confirmed by the entrance of Triapine into widespread NCI clinical trials. In this NHMRC Renewal, we will perform pharmacological and preclinical studies to promote the development of BpT chelators as novel anti-tumour agents.
A Cluster RCT Of A Novel Psychological Intervention To Reduce Depression Among At-risk Older Adults Transitioning To Residential Aged Care
Funder
National Health and Medical Research Council
Funding Amount
$893,152.00
Summary
Depression is common in aged care facilities, with many older adults finding the transition extremely difficult. We have developed a simple intervention to help new residents, including those with dementia, to adjust to life in aged care. This program focuses on key aspects of psychological wellbeing, and is designed for widespread use in aged care. We will evaluate the intervention to determine if it is superior to current care approaches in reducing depression and improving quality of life.
Improving Treatment Strategies For Chronic Alphaviral Arthritic Diseases
Funder
National Health and Medical Research Council
Funding Amount
$643,624.00
Summary
Chikungunya virus and Ross River virus cause epidemics of acute and chronic arthritic disease in humans, which is often poorly managed with current treatments. This grant seeks to understand the mechanisms that give rise to disease in order to identify improved treatment strategies. Both the persistence of viral replication in joint tissues and unnecessary inflammatory responses appear to be important factors driving chronic disease.
Probiotic Prawn Oral Immunotherapy (ProPIT) For Treatment Of Prawn Allergy
Funder
National Health and Medical Research Council
Funding Amount
$1,865,369.00
Summary
A ‘curative’ food allergy treatment is needed to prevent deaths and improve care. We recently showed that probiotic peanut oral immunotherapy (PPOIT) was highly effective for treating peanut allergy. 82% of PPOIT treated children gained tolerance compared to 4% of the placebo group. We will now test the combined probiotic-food OIT approach for treating prawn allergy. If successful, we will have identified the first treatment for prawn allergy and a platform treatment for other food allergies.
Driving Change: Using Emergency Department Data To Reduce Alcohol-related Harm
Funder
National Health and Medical Research Council
Funding Amount
$1,468,026.00
Summary
The proposed project is a system change within partner emergency departments, providing them the information and tools to act on both risky alcohol consumption in individual patients and the sources of alcohol in the community which cause the harm they experience. Most importantly, the proposed public health interventions act as a tool for emergency departments to regularly raise awareness with the public and policymakers regarding the impact of alcohol on patients, clinicians and hospitals.
Special Research Initiatives - Grant ID: SR180100027
Funder
Australian Research Council
Funding Amount
$1,086,676.00
Summary
Integrated, scalable technology solutions for PFAS removal and destruction. This project aims to deliver a ready-to-deploy and scalable modular technology that is capable of removing poly- and per-fluoroalkyl substances (PFAS) from a variety of water sources, including groundwater and surface waters, to make them virtually PFAS-free and therefore safe for human consumption. The concept draws on recent advances in water treatment and electrochemistry that is based on ion exchange, nanofiltration ....Integrated, scalable technology solutions for PFAS removal and destruction. This project aims to deliver a ready-to-deploy and scalable modular technology that is capable of removing poly- and per-fluoroalkyl substances (PFAS) from a variety of water sources, including groundwater and surface waters, to make them virtually PFAS-free and therefore safe for human consumption. The concept draws on recent advances in water treatment and electrochemistry that is based on ion exchange, nanofiltration and advanced oxidation. A risk-based framework will be developed to deliver fit-for-purpose solutions at minimal cost for stakeholders and taxpayers. This project is expected to benefit the residents who live in the vicinity of contaminated waterways or consume water from polluted sources.Read moreRead less